Islay Capital Management’s FibroBiologics FBLG Stock Holding History

Islay Capital Management’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$160	Hold	169	–	–	﹤0.01%	221
2026 Q1	$223	Sell	169 -1	-0.6%	-$6	﹤0.01%	197
2025 Q4	$763	Hold	170	–	–	﹤0.01%	201
2025 Q3	$1.85K	Buy	170 +147	+639%	+$1.76K	﹤0.01%	192
2025 Q2	$280	Buy	+23	New	+$415	﹤0.01%	198

Other funds holding FBLG

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Islay Capital Management's FBLG Position: Q2 2026 in Review

Islay Capital Management held its FibroBiologics (FBLG) position steady in Q2 2026 at 169 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #221.

Islay Capital Management first reported a position in FBLG in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.85K in Q3 2025. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

Islay Capital Management held 169 shares of FibroBiologics worth $160 as of Q2 2026.
Islay Capital Management left its FibroBiologics share count unchanged in Q2 2026.
FibroBiologics made up ﹤0.01% of Islay Capital Management's portfolio in Q2 2026, its #221 holding.
Islay Capital Management first reported a position in FibroBiologics in Q2 2025 and has held it in 5 quarters since.
Islay Capital Management's FibroBiologics position peaked at $1.85K in Q3 2025.
16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on Islay Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.